---
filename: gi-bleeding.md
id: gi-bleeding
title: GI Bleeding
slug: gi-bleeding
tags: [gastroenterology, inpatient, night-float, hemorrhage, critical-care]
level: resident
estimated_time_min: 18
version: 2026-02-21
source: IM_NightFloat_Engine
---

# GI Bleeding

## Panic Card
- Secure ABCs; two large-bore IVs; start balanced crystalloids; target **MAP ≥65 mmHg**; if septic physiology suspected, begin sepsis bundle and **antibiotics within 1 h**. citeturn2search41turn2search46
- Transfuse packed RBCs for **Hb <7 g/dL** (consider **8 g/dL** if CAD/orthopedic/cardiac surgery); activate MTP if ongoing shock. citeturn2search35turn2search40
- Suspected variceal UGIB: start **octreotide 50 mcg IV bolus, then 50 mcg/h** and **ceftriaxone 1 g IV daily (7 d)**; arrange endoscopy **≤12 h**. citeturn2search15
- Nonvariceal UGIB: give **erythromycin 250 mg IV 20–90 min pre‑EGD**; plan EGD **≤24 h**; initiate post‑hemostasis **high‑dose PPI**. citeturn2search24turn2search29
- Brisk hematochezia with instability: obtain **CTA A/P now** to localize and enable IR embolization; urgent colonoscopy rarely improves outcomes in severe LGIB. citeturn2search59turn2search34
- Confirm Before Proceed: use **andexanet alfa/idarucizumab** only for life‑threatening DOAC‑associated bleeding given thrombotic risk; consider **4F‑PCC** if specific antidote unavailable. citeturn2search63turn2search61

## Brief Overview
- GI bleeding on nights splits into UGIB (proximal to ligament of Treitz) and LGIB (colonic) with different first moves: stabilize, risk‑stratify, choose endoscopy vs CTA appropriately; early resuscitation and restrictive transfusion strategy (**Hb <7 g/dL**) reduce harm. **Guideline Must‑Know:** AABB 2023 endorses restrictive thresholds, with **8 g/dL** reasonable for selected cardiac contexts. citeturn2search35
- **Guideline Must‑Know:** For hospitalized UGIB, perform EGD **within 24 h** after stabilization; pre‑endoscopic **erythromycin 250 mg IV** improves visualization and reduces repeat EGD; high‑dose PPI is recommended after endoscopic hemostasis of ulcer bleeding. citeturn2search24turn2search29
- **Guideline Must‑Know:** For variceal hemorrhage, start vasoactive therapy (octreotide or terlipressin) plus **ceftriaxone** at presentation; perform band ligation early (typically **≤12 h**); consider **preemptive TIPS** in high‑risk patients (e.g., Child‑Pugh **C 10–13** or **B with active bleeding**). citeturn2search15turn2search10
- **Guideline Must‑Know:** For LGIB with hemodynamic significance, **CTA** is preferred for localization and guides transcatheter embolization; routine urgent colonoscopy within 24 h has not shown outcome benefit; most inpatient colonoscopies can be **non‑urgent** (≤14 d if stable). citeturn2search59turn2search34
- **Guideline Must‑Know:** Risk scores: use **Glasgow‑Blatchford (GBS)** at first assessment to identify very‑low‑risk UGIB (GBS **0–1**) for potential discharge; GBS outperforms pre‑endoscopic Rockall for predicting interventions. citeturn2search24turn2search58
- **Guideline Must‑Know:** Transfusion/product targets: maintain **platelets >50 ×10⁹/L** for active bleeding needing hemostasis; reverse **warfarin** with PCC for life‑threatening bleeding; for DOACs, use **andexanet** (apixaban/rivaroxaban) or **idarucizumab** (dabigatran) when bleeding is life‑threatening; otherwise hold drug/supportive care. citeturn2search59turn2search63
- In UGIB, give **PPI after** endoscopic hemostasis (continuous or intermittent high‑dose for 72 h, then BID for 2 weeks); pre‑EGD PPI has uncertain benefit and is not strongly recommended for outcomes. citeturn2search24
- **Guideline Must‑Know:** Endoscopic hemostasis options for ulcers include thermal (heater probe/bipolar), mechanical (clips), injection (epinephrine as adjunct only), with **hemostatic powder** for active bleeding and **over‑the‑scope clips** for recurrent bleeding; consider IR embolization if endoscopy fails. citeturn2search24
- Distinguish variceal stigmata (cirrhosis, portal hypertension signs) from nonvariceal causes; if uncertain and unstable, treat as variceal (octreotide + antibiotics) while arranging urgent EGD. **Confirm Before Proceed:** avoid delaying vasoactive therapy for diagnostic certainty. citeturn2search15
- **Guideline Must‑Know:** Sepsis bundle if infection suspected: **30 mL/kg** crystalloid for hypoperfusion, dynamic fluid assessment, and **MAP 65 mmHg** with norepinephrine first‑line. GI bleeding with fever/ascites or aspiration risk warrants vigilance for sepsis. citeturn2search41turn2search46
- In LGIB, after CTA‑positive localization, **IR embolization within ~90 min** can control bleeding with high technical success; monitor for bowel ischemia; coordinate with GI for subsequent diagnostic colonoscopy when stable. citeturn2search34
- **Guideline Must‑Know:** Antithrombotic resumption: resume **aspirin for secondary prevention** once hemostasis achieved; individualized timing for anticoagulation (often ~7 days) balancing rebleed vs thrombosis; document plan with GI/Cardiology/Heme. citeturn2search59
- ICU triggers include refractory hypotension, transfusion needs **>4 units/24 h**, persistent hematemesis/melena with rising lactate, or escalating oxygen/airway support; consider early anesthesia involvement for high‑risk EGD. citeturn2search41
- **Guideline Must‑Know:** For brisk hematochezia with shock, remember an **upper source is possible**; consider EGD when suspicion moderate/high even if CTA pending or negative. citeturn2search26
- Pitfalls: over‑transfusion raising portal pressures; failing to give **ceftriaxone** in variceal bleed; delaying vasoactive therapy; attempting urgent colonoscopy in unstable LGIB instead of **CTA→IR**; not using erythromycin pre‑EGD in UGIB. citeturn2search15turn2search59turn2search24
- **Guideline Must‑Know:** Post‑EGD ulcer bleed: high‑dose PPI **continuous (8 mg/h) or intermittent** for 72 h is acceptable; repeat endoscopy for rebleeding; IR embolization if endoscopic therapy fails. citeturn2search24
- **Guideline Must‑Know:** Early antibiotic prophylaxis in variceal bleeding reduces infections and mortality; **ceftriaxone 1 g daily** preferred in areas with high quinolone resistance. citeturn2search15
- **Guideline Must‑Know:** Preemptive **TIPS** improves outcomes in selected high‑risk variceal bleeders; coordinate urgently with Hepatology/IR; document Child‑Pugh/MELD and failure criteria. citeturn2search15turn2search10

## Top ICU/Consult Triggers
- Persistent hypotension requiring vasopressors or **lactate >4 mmol/L** despite resuscitation. citeturn2search41
- Transfusion requirement **>4 pRBC units in 24 h** or anticipated massive transfusion. citeturn2search34
- Ongoing hematemesis/hematochezia with Hb drop **>2 g/dL** and tachycardia despite fluids. citeturn2search24
- Suspected variceal bleeding in **Child‑Pugh C** or **B with active bleeding** (consider early TIPS). citeturn2search15
- Increasing oxygen needs or airway compromise from aspiration/encephalopathy. citeturn2search41

## Orders to Place Now
- Order: Type and crossmatch — {units_pRBC: 2, hold_samples: true} citeturn2search35
- Order: Pantoprazole infusion — {80 mg IV bolus, then 8 mg/h x 72 h; switch to PO BID x 14 d post‑EGD if ulcer hemostasis} citeturn2search24
- Order: Erythromycin pre‑EGD — {250 mg IV over 20–30 min, give 20–90 min before endoscopy} citeturn2search24turn2search29
- Order: Octreotide infusion (if variceal suspected) — {50 mcg IV bolus, then 50 mcg/h infusion} citeturn2search15
- Order: Ceftriaxone prophylaxis (variceal bleed) — {1 g IV q24h x 7 days} citeturn2search15
- Order: CT Angiography Abdomen/Pelvis (LGIB with instability) — {indication: ongoing hematochezia with shock; proceed to IR if positive} citeturn2search59turn2search34

## ABIM‑Style Question 1

### Stem
A 58‑year‑old man with melena and orthostasis is admitted. Vitals improve after fluids. Hb is 7.2 g/dL. He is not on anticoagulants. You plan endoscopy.  

### Options
A. Start continuous PPI now and schedule elective EGD in 48–72 hours  
B. Administer erythromycin 250 mg IV 30 minutes before EGD and perform EGD within 24 hours  
C. Give octreotide infusion and ceftriaxone empirically for all UGIB  
D. Transfuse to a goal hemoglobin of 10 g/dL before EGD  
E. Obtain CTA abdomen/pelvis now instead of EGD  

### Correct answer
B

### Rationale
ACG UGIB guidance suggests **EGD within 24 h** after stabilization and recommends **erythromycin 250 mg IV 20–90 min prior** to improve visualization and reduce repeat procedures; high‑dose PPI is recommended **after** endoscopic therapy for ulcer bleeding. Restrictive transfusion (**Hb <7 g/dL**) is preferred; routine octreotide/antibiotics is reserved for suspected variceal bleeding. citeturn2search24turn2search29turn2search35

## Second ABIM‑Style Case (Pitfall Variant)

### Stem
A 72‑year‑old woman on apixaban for AF presents with brisk hematochezia, SBP 82 mmHg, HR 122, Hb 8.1 g/dL. After fluids and 1 unit pRBC, she remains unstable.

### Options
A. Urgent colonoscopy within 6 hours after a rapid prep  
B. Start octreotide infusion empirically and schedule EGD tomorrow  
C. CT angiography of abdomen/pelvis now to localize bleeding with plan for IR embolization if positive  
D. Tagged RBC scan to localize bleeding before any other imaging  
E. Start high‑dose IV PPI and observe 24 hours  

### Correct answer
C

### Rationale
For hemodynamically significant LGIB, **CTA is recommended** to localize bleeding and expedite **IR embolization**; urgent colonoscopy has not improved key outcomes in severe LGIB. The pitfall is defaulting to colonoscopy first in unstable LGIB. If bleeding is life‑threatening and driven by a recent factor Xa inhibitor, consider **andexanet** per institutional criteria. citeturn2search59turn2search34

What changed the decision here?

## Check‑Yourself Micro‑Questions
- Q: Transfuse RBCs at what hemoglobin for most stable adults?  
  A: **<7 g/dL** (consider **8 g/dL** with cardiovascular disease/orthopedic/cardiac surgery). citeturn2search35
- Q: EGD timing for hospitalized UGIB after stabilization?  
  A: Perform within **24 hours**; sooner if ongoing instability after resuscitation. citeturn2search24
- Q: First‑line imaging for unstable LGIB with active hematochezia?  
  A: **CT angiography** to localize and facilitate IR embolization. citeturn2search59turn2search34
- Q: Initial variceal bundle at presentation?  
  A: **Vasoactive agent** (e.g., octreotide), **ceftriaxone**, and early EGD with band ligation. citeturn2search15
- Q: Erythromycin pre‑EGD dose?  
  A: **250 mg IV** 20–90 minutes before endoscopy. citeturn2search24

## Guidelines & Key References
- ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding (2021). citeturn2search24
- ACG Updated Guideline: Acute Lower Gastrointestinal Bleeding (2023). citeturn2search59
- AASLD Practice Guidance: Portal Hypertension & Variceal Bleeding (2023) and Baveno VII Consensus (2022). citeturn2search15turn2search10
- AABB International Guidelines for Red Blood Cell Transfusion (2023). citeturn2search35
- Surviving Sepsis Campaign: Management of Sepsis and Septic Shock (2021). citeturn2search41

## CDI: What to Document Clearly Tonight
- Acute upper GI bleeding — etiology: {peptic ulcer vs variceal vs other}; severity: {hemorrhagic shock vs acute blood loss anemia}; objective evidence: {Hb trend, lactate, hemodynamics, EGD findings}; treatment: {endoscopic hemostasis type, vasoactive infusion, PPI/antibiotics, transfusion units}.  
- Acute lower GI bleeding — suspected source: {diverticular vs angiodysplasia vs post‑polypectomy}; severity: {ongoing transfusion needs, CTA localization}; objective evidence: {CTA result, IR embolization performed}; treatment: {IR embolization details, bowel prep/colonoscopy timing}.  
- Coagulopathy/anticoagulant‑related hemorrhage — drug and last dose; reversal used ({PCC/andexanet/idarucizumab}); risk–benefit justification; thrombotic risk plan and restart timing.  
- Shock (type and criteria) — specify **hypovolemic** vs mixed **septic**; document **MAP**, vasopressor use, fluids, urine output, lactate response.  
- Aspiration risk/encephalopathy — airway protection decisions, oxygen/vent settings, antibiotics if indicated.
